Bora Biologics

Executive Summary

Bora Biologics is a technology-driven Contract Development and Manufacturing Organization (CDMO) specializing in mammalian and microbial development and manufacturing for biologics and biosimilars. Founded in 2014 and headquartered in San Diego, the company operates FDA-registered facilities in the United States and Taiwan, offering end-to-end services from process development through commercial-scale GMP production. Its mission is to accelerate client access to advanced technologies and comprehensive manufacturing capabilities to transform the future of medicine. As a private, pre-clinical stage company, Bora Biologics focuses on providing high-quality biologics manufacturing support to a growing client base seeking reliable CDMO partners to bridge the gap between discovery and commercialization. The company's strategic positioning with dual U.S. and Taiwan facilities enables it to leverage cost efficiencies and regulatory expertise across two major markets. In the competitive CDMO landscape, Bora Biologics differentiates itself through its technology-driven approach and commitment to accelerating client timelines. With the biologics market expanding, particularly in biosimilars and complex antibody modalities, Bora Biologics is well-poised to capture demand. However, as a private company with no disclosed financials or pipeline clients, its growth trajectory remains uncertain. The executive summary reflects a cautiously optimistic view, with conviction tempered by the lack of public milestones.

Upcoming Catalysts (preview)

• Q3 2026Announcement of New Client Manufacturing Agreement70% success
• Q4 2026Expansion of Commercial-Scale Capacity at Taiwan Facility60% success
• Q2 2026Launch of Novel Platform Technology for Antibody Production50% success